

# Subject Index

## A

Abnormal behavior 63  
 Abstinence 41  
 Acetylcholine interaction 191  
 Acquisition 245  
 Activity 29  
 Adenylate cyclase 215, 287  
 Aggression 191  
 Alpha-methyl-*p*-tyrosine 85  
 Alternating discrimination 131  
 Amino-oxyacetic acid 85  
 Amobarbital 167  
 Amphetamine 29, 173  
   *d*- 113, 167, 225  
   *dl*- 91  
 Amylobarbitone 91  
 Animal 219  
 Antagonism 33  
 Anticholinergics 139  
 Antidepressant 219  
   — agents 197  
 Apomorphine 63, 109, 139, 145, 301  
 Arousal 57  
 Atropine 145, 191  
 Avoidance behavior  
   — continuous 69, 75  
   — discriminative 63

## B

Barbiturates 57, 167  
 Basal ganglia 281  
 Behavior 17  
 Benzodiazepines 259  
 Biochemical classification 219  
 Body temperature 113  
 Brain areas 235  
   — monoamines 179  
   — stem 197

## C

Calcitonin and Parathormone 187  
 Calcium 187  
 Caloric intake 79  
 Cannabidiol 267  
 Cannabinol 267  
 Carboxyhemoglobin 263  
 Catecholamines 1, 63, 97, 119  
 Cats 197, 271, 281  
 Candate-putamen 23  
 Central dopaminergic influences 109  
 Chained schedules 245  
 Chlorpromazine 101, 301  
   — metabolites 101  
 Chronic phenothiazine treatment 101  
 Clinical 219  
 Clonidine 109, 145  
 Clozapine 97

## CNS

— "depressants" 33  
 — "stimulants" 33  
 Competition 205  
 Contingency 145  
 Convulsions 49  
 Copulatory behavior 301  
 Cortico-steroid levels 75

## D

Defecation 249  
 Dependence  
   — single dose 41  
 Depression 139, 205  
 Dextimide 191  
 Diarrhea 191  
 Diazepam 69, 75, 271  
 Diprenorphine 41  
 Dopamine 1, 23, 97, 139, 173, 191, 259,  
   281, 287, 301  
   — agonists 125  
   — antagonists 125, 301  
   — beta hydroxylase 1  
   — receptor sensitivity 253  
 L-Dopa 63, 281  
 Drive 145  
 DRL schedule 249  
 Drug addiction 117  
   — dependence 113  
   — discrimination 33  
   — mixture 91  
   — stimuli 167  
 Drugs 245

## E

ECS 179  
 Electric shocks 17  
 Emotional behavior 271  
 Eniprazole 271  
 Environment 117  
 Epinephrine 215  
 Eserine 145  
 Ethanol 29, 49, 235, 275  
   — administration, chronic 253  
 Experimental setting 79  
 Exploratory response 91

## F

Fear conditioning  
   — discriminative 69  
   — Parlovian 75  
 FG 4963 139  
 FI schedule 225  
 Food deprivation 49  
   — intake 113  
 Footshock 91  
 Frustration 249

## G

GABA 173, 259  
 Gamma-amino-butyric acid 85  
 General activity 125  
 Gerbils 33  
 Glycine 259  
 Gnawing 139

## H

Habituation 91, 167  
 Haloperidol 97, 109, 145, 215  
 Head twitches 259  
 Heart rate 275  
 Heroin 29  
 Hexobarbital 159  
 Hole-board 173  
 Human subjects 1, 79, 101, 205, 215, 263,  
   275, 307  
 11-Hydroxy- $\Delta^8$ -tetrahydrocannabinol 267  
 5-Hydroxytryptamine 287  
 Hyperthermia 17, 57  
 Hypothalamic stimulation 271  
 Hypothalamus 23, 97, 197

## I

Intracerebral dopamine application 253

## K

Kynurenine 205

## L

Learning 307  
 Light-onset reward 91  
 Lithium 187, 215  
 Locomotor activity 119, 173, 253  
 Lysergic acid diethylamide 301

## M

Magnesium 187  
 Mania 205, 215  
 Marihuana 275  
   — smoking 79  
 Memory 131, 307  
   — consolidation 109  
 Mental illness 1  
 Methylatropine 145  
 Methylscopolamine 191  
 Mice 41, 117, 139, 259, 267  
   — inbred 29  
 Monkeys, squirrel 225  
 Morphine 57, 117, 225  
   — addiction 191  
   — dependence 267  
   — tolerance 125  
 Motor behavior 113  
 Multiple unit activity 197, 235

**N**

Naloxone 41, 225, 267  
 Naltrexone 41  
 Narcotic withdrawal 191  
 Neuroleptics 97, 287  
 Nicotine 145  
 Nootropyl 307  
 Noradrenaline 97  
 Norepinephrine 1, 259  
 Normal human 307  
 Nucleus accumbens 173, 253

**O**

Ontogenesis 119  
 Oxprenolol 17

**P**

Pairing 145  
 Para-chlorophenylalanine 23, 85  
 Parkinsonian symptoms 101  
 Peripheral adrenergic influences 109  
 Pharmacologic 219  
 Phenoxybenzamine 63, 109, 145  
 Phentolamine 109  
 Pigeons 245  
 Pigs 69, 75  
 Pilocarpine 159, 191  
 Pimozide 63, 301  
 Piracetam 307  
 Plasma amino acids 205  
 Polydipsia  
 — schedule induced 49

Profile 219

Prolactin 101

**R**

Rabbits 57, 235  
 Rats 17, 23, 41, 49, 63, 85, 91, 97, 109,  
 113, 119, 125, 131, 145, 159, 167, 173,  
 179, 187, 191, 249, 253, 271, 287, 301  
 Rats and drug interaction 159  
 REM Sleep 197  
 Reserpine 281  
 Reset contingencies 245  
 Response inhibition 249  
 — transients 249

**S**

Schedule-controlled behavior 225  
 Schizophrenia 1  
 Scopolamine 131  
 Self-stimulation 97  
 — intracranial 23  
 Serotonin 23, 259, 301  
 Serum 187  
 Shuttle avoidance 109  
 — behavior 145  
 Stereotyped behavior 113, 173  
 Storage 131  
 Strychnine 29  
 Sudden reinforcement schedule changes  
 249  
 Supersensitivity 125  
 Synthesis 179

**T**

Tandem schedules 245  
 Target sites 235  
 Taste aversions 167  
 Taurine 249  
 Temporal discrimination 249  
 $\Delta^9$ -Tetrahydrocannabinol 267  
 $\Delta^8$ -Tetracannabinol 267  
 Thymoleptics 139  
 Thyrotropin-releasing hormone 197  
 Time perception 275  
 — production 275  
 Tobacco withdrawal 263  
 Tolerance 101, 113, 167  
 Transfer 33  
 Transport 205  
 TRH 57  
 Tryptophan 205  
 Turnover 179  
 Tyrosine hydroxylation 119

**U**

Uptake 179

**V**

Variable intertrial spatial  
 alternation 131

**W**

Water availability 49  
 Weight gain 79  
 Wet shakes 191

# Clinical Pharmacology of Anti-Epileptic Drugs

International Symposium. Workshop on the Determination of  
Anti-Epileptic Drugs in Body Fluid II (WODADIBOF II)  
Held in Bethel, Bielefeld, Germany, 24–25 May 1974

Editors: H. Schneider; D. Janz; C. Gardner-Thorpe; H. Meinardi;  
A.L. Sherwin

129 figures, 89 tables. X, 370 pages. 1975

Cloth DM 128,—; US \$52.50

ISBN 3-540-06987-9

Prices are subject to change without notice

The proceedings of the Bethel meeting, apart from giving a record and naturally emphasizing the more recently introduced drugs, supplement the currently available reference books on the subject. The volume contributes to present knowledge about anti-epileptic drugs, gives the latest findings and theories on their pharmacokinetics, clinical pharmacology and evaluation as well as advances in analytical methods and presents controversial points of view discussed by experts in the field.

This manual is intended as a tool for both the clinician and the scientific worker in pharmacology, epileptology, neurology, pediatrics and neurophysiology as they relate to epileptic disorders. It serves not only to expand and augment knowledge about anti-epileptic drugs but should also improve the treatment of epilepsy patients by basing therapy to a greater extent than hitherto on pharmacokinetic principles.



Springer-Verlag  
Berlin  
Heidelberg  
New York

## Contents:

Pharmacokinetics.  
Pharmacology of Anti-Epileptic Drugs.  
Various Aspects (Varia).  
Quality Control and Standardization.  
Methodology of Determination.  
Dictionary of Anti-Epileptic Drug Synonyms, Chemical Names and  
Nonproprietary Names.  
Subject Index.

# All you may ever need to know about the **SCIENCE CITATION INDEX®** but never found time to ask.



If you've heard about the *Science Citation Index*, wondered how it works or compares with traditional subject indexes, here's your chance to get the full story.

A new, comprehensive booklet discusses every facet of this unique indexing system. And it's available to you without cost or obligation.

Just off press, this booklet is full of facts, figures, theory and how-to-use-it information. For example, you'll find discussions of:

- How the SCI® employs citation and Permuterm® subject indexing to avoid use of ambiguous terminology.
- How the SCI covers over 90% of the significant scientific and technical journal literature.
- What is citation indexing?
- How the SCI's sophisticated, computer-based information processing reduces the time lag between original publication and indexing to a bare minimum.
- How to perform four basic types of literature searches—with sample indexing entries shown in detail.

**So if you want to know all about the SCI, now's the time to ask. Send for your free booklet or ask for any reasonable number you may need for your organization.**

Please send me \_\_\_\_\_  
copies of your new booklet on the  
*Science Citation Index®* without cost or obligation.

Name \_\_\_\_\_

Organization \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_

State \_\_\_\_\_

ZIP \_\_\_\_\_

Country \_\_\_\_\_

Telephone \_\_\_\_\_

**ISI®** Institute for Scientific Information®

325 Chestnut St., Phila., Pa. 19106, U.S.A., Tel: (215) 923-3300, Cable: SCINFO, Telex: 84-5305

SP 440

©1975 ISI



